CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 29, 2019--
AVEO Oncology (NASDAQ: AVEO) today announced that Mike Ferraresso,
Senior Vice President, Business Analytics and Commercial Operations,
will present at the 2019 BIO International Convention in Philadelphia on
Wednesday, June 5, 2019 at 4:30 p.m. EDT.
A live webcast of the presentation can be accessed by visiting the
investors section of the Company’s website at www.aveooncology.com.
A replay of the webcast will be archived for 30 days following the
AVEO Pharmaceuticals, Inc. (the “Company” or “AVEO”) is a
biopharmaceutical company seeking to advance targeted medicines for
oncology and other unmet medical needs. The Company is working to
develop and commercialize its lead candidate tivozanib in North America
as a treatment for RCC. The Company has sublicensed tivozanib (FOTIVDA®)
for oncological indications in Europe and other territories outside of
North America. Tivozanib is approved in the European Union, as well as
Norway and Iceland, for the first-line treatment of adult patients with
RCC and for adult patients who are vascular endothelial growth factor
receptor and mTOR pathway inhibitor-naïve following disease progression
after one prior treatment with cytokine therapy for RCC. The Company
also has clinical collaborations to study tivozanib in combination with
immune checkpoint inhibitors in RCC and in hepatocellular carcinoma. In
addition, a new formulation of tivozanib is in pre-clinical development
for the treatment of age-related macular degeneration. As part of the
Company’s strategy, the Company has also entered into partnerships to
help fund the development and commercialization of its other product
candidates. Ficlatuzumab, a hepatocyte growth factor inhibitory
antibody, is currently being tested in several investigator sponsored
studies jointly funded by the Company and one of its development
partners for the potential treatment of head and neck squamous cell
carcinoma, acute myeloid leukemia, and pancreatic ductal adenocarcinoma.
The Company’s partner for AV-203, an anti-ErbB3 monoclonal antibody, is
planning to initiate clinical studies in China in 2019 in esophageal
squamous cell carcinoma and has committed to funding the development of
AV-203 through proof-of-concept. The Company has recently regained the
rights to AV-380, a humanized IgG1 inhibitory monoclonal antibody
targeting growth differentiation factor 15, a divergent member of the
TGF-ß family, for the potential treatment of cancer cachexia, and is
working to initiate preclinical toxicology studies in 2019 to support
the potential filing of an investigational new drug application with the
FDA. The Company is evaluating options for the development of AV-353, a
preclinical asset which targets the Notch 3 pathway.
For more information, please visit the Company’s website at www.aveooncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO within
the meaning of the Private Securities Litigation Reform Act of 1995 that
involve substantial risks and uncertainties. All statements, other than
statements of historical fact, contained in this press release are
forward-looking statements. Actual results or events could differ
materially due to a number of important factors, including risks
discussed in the section titled “Risk Factors” in AVEO’s most recent
Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its
other filings with the SEC. The forward-looking statements in this press
release represent AVEO’s views as of the date of this press release.
AVEO anticipates that subsequent events and developments may cause its
views to change. While AVEO may elect to update these forward-looking
statements at some point in the future, it specifically disclaims any
obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing AVEO’s views as of any date
other than the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005218/en/
Source: AVEO Pharmaceuticals, Inc.
David Pitts, Argot Partners